Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 488 Cr.
- Current Price ₹ 407
- High / Low ₹ 425 / 230
- Stock P/E 23.2
- Book Value ₹ 84.1
- Dividend Yield 0.00 %
- ROCE 21.1 %
- ROE 22.6 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 209 days.
- Promoter holding has decreased over last 3 years: -7.51%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|
| 22 | 32 | 45 | 87 | 129 | 141 | |
| 19 | 25 | 36 | 72 | 101 | 109 | |
| Operating Profit | 3 | 6 | 8 | 15 | 28 | 31 |
| OPM % | 12% | 20% | 18% | 17% | 22% | 22% |
| 1 | 1 | 2 | 8 | 10 | 8 | |
| Interest | 0 | 0 | 1 | 4 | 5 | 4 |
| Depreciation | 0 | 0 | 1 | 5 | 6 | 6 |
| Profit before tax | 3 | 7 | 9 | 14 | 27 | 30 |
| Tax % | -32% | 8% | 32% | 23% | 29% | |
| 4 | 6 | 6 | 10 | 19 | 22 | |
| EPS in Rs | 4.94 | 5.24 | 5.51 | 10.22 | 15.96 | 17.73 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 60% |
| TTM: | 66% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 46% |
| TTM: | 31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 31% |
| 1 Year: | 36% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 19% |
| Last Year: | 23% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 8 | 12 | 12 | 12 | 12 |
| Reserves | -3 | 34 | 41 | 53 | 88 |
| 2 | 8 | 18 | 54 | 73 | |
| 7 | 9 | 16 | 37 | 62 | |
| Total Liabilities | 14 | 63 | 87 | 156 | 236 |
| 1 | 3 | 21 | 44 | 61 | |
| CWIP | 0 | 5 | 4 | 2 | 18 |
| Investments | 0 | 3 | 4 | 11 | 8 |
| 12 | 51 | 58 | 99 | 149 | |
| Total Assets | 14 | 63 | 87 | 156 | 236 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -0 | -19 | 2 | -4 | 5 | |
| -0 | -10 | -20 | -14 | -37 | |
| 1 | 42 | 11 | 14 | 34 | |
| Net Cash Flow | 0 | 14 | -7 | -4 | 2 |
| Free Cash Flow | -1 | -26 | -16 | -15 | -29 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -8% | -294% | 56% | 4% | 43% |
Ratios
Consolidated / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 83 | 139 | 110 | 116 | 209 |
| Inventory Days | 95 | 129 | 156 | 226 | 173 |
| Days Payable | 134 | 87 | 94 | 119 | 182 |
| Cash Conversion Cycle | 44 | 182 | 173 | 224 | 199 |
| Working Capital Days | 49 | 275 | 205 | 144 | 134 |
| ROCE % | 23% | 15% | 18% | 21% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Africa Revenue Share % ・Standalone data |
|
||||||
| Export Revenue Share (Direct + Merchant Exports) % ・Standalone data |
|||||||
| Tablet Revenue Share % ・Standalone data |
|||||||
| Products in Portfolio count ・Standalone data |
|||||||
| Consolidated Manufacturing Capacity - Tablets Million per Month ・Standalone data |
|||||||
| Capacity Utilization % ・Standalone data |
|||||||
| Countries Present Globally count ・Standalone data |
|||||||
| Export Market Product Registrations In Process (Cumulative Pipeline) count ・Standalone data |
|||||||
| Export Market Products Registered (Cumulative) count ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
- Trident Lifeline submits FY2025-26 annual secretarial compliance report; no non-compliances observed.
-
Board Meeting Intimation for Consideration And Approval Of Un-Audited Financial Result For Half Year Ended 30.09.2026
- Board meets on October 26, 2026 to approve September-half-year results and consider first interim dividend.
-
Announcement under Regulation 30 (LODR)-Allotment
- Board allotted 24,000 equity shares on October 17, 2026, upon warrant conversion, raising paid-up capital to Rs. 11.98 crore.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. On October 17, 2026, In Terms Of Second Proviso To Regulation 30(6) Of SEBI (LODR) Regulations, 2015
- Board allotted 24,000 equity shares on warrant conversion, receiving Rs. 47.88 lakh.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Please find attached herewith copies of the newspaper advertisements published in Financial Express (English) and Financial Express (Gujarati) regarding the corrigendum to the Notice of …
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
Business Overview:[1]
TLL is a Surat-based pharmaceutical and healthcare-products company. It began as an export-oriented formulations company using third-party and loan-licence manufacturing. It is now evolving into a vertically integrated healthcare-manufacturing platform through its own and subsidiary facilities.